Recent information from the U.S. Food and Drug Administration (FDA) states (Prioritization of MABS During Resources Shortages) that currently available monoclonal antibodies bamlanivimab and etesevimab, as well as casirivimab-indevimab (REGEN-COV) are likely ineffective against the Omicron variant of SARS-CoV-2.
Sotrovimab is expected to retain activity against the Omicron variant, but we currently only have six doses. We have ordered more but unfortunately, we do not know how many doses we will receive or when it will arrive.
The prevalence of the Omicron variant is geographically specific with latest reports suggesting it is greater than 80% in Central New York.
Due to our limited supply of Sotrovimab the Incident Management Team approved restricting ordering Sotrovimab to NYSDOH risk classification 1a which is:
- Any age with moderate to severe immunocompromise regardless of vaccine status OR
- Age 65 and older and not fully vaccinated with at least one risk factor for severe illness OR
- Age 65 or older that is a resident of a long-term care facility.
Please do not order Sotrovimab for any patients that do not meet the 1a criteria.
As our supply increases we will update this information.
In light of the prevalence of the Omicron variant in Central New York, it is recommended that providers make a risk-benefit decision whether or not to use the bamlanivimab/etesevimab or casirivimab-indevimab (REGEN-COV) that are currently available at SJH to treat patients for whom monoclonal antibody therapy is appropriate.
Please contact the Pharmacy at 315.448.5195 with any questions.